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CHAPTER 3 
Strategies for the Management of 
Nonsecreting Pituitary Adenomas 
William T. Couldwell, MD, and Martin H. Weiss, MD 
The twO objectives of treating pituitary tu-
mors are: (1) relief of signs and symptoms at-
tributable ro mass effect, and (2) correction 
of hypo- or hypersecretion of ade-
nohypophyseal hormones. 7 When nonsecret-
ing tumors are specifically considered, correc-
tion of endocrine abnormalities may be of less 
consequence than hormonal excess, but con-
tinued growth of the lesion may precipitate 
hypopituitarism. 
Radioimmunoassay has revolutionized the 
diagnosis and management of pituitary tu-
mors. Complementary immunocytochemical 
methods have rendered original mor-
phometric histological classification methods 
of pituitary tumors clinically obsolete. In 
conjunction with advances in radiographic 
imaging and electron microscopy, the detec-
tion, diagnosis, and definition of these le-
sions have been greatly enhanced and our un-
derstanding of the nature of the production 




Compared ro hormonally active tumors, 
nonfunctioning pituitary adenomas more fre-
quently present with symptoms of tumor 
mass effect, such as headache, visual failure, 
or hypopituitarism. Null cell tumors are Sta-
tistically the most common type of adenoma 
found in the pituitary, and present more fre-
quently later in life than secreting tumors. 
The classic visual triad produced by larger 
tumors is characterized by optic disc pallor, 
early loss of central visual acuity, and visual 
field defects (bitemporal hemianopsia). t11 
Nonsecreting pituitary adenomas may be 
defined as those that are apparently inactive 
clinically and biochemically. Apparent inac-
tivity does not rule out the potential for se-
cretion of an as-yet undetectable hormone or 
its precursor, or the synthesis of a known 
hormone in insufficient quantities ro be de-
tected by immunoperoxidase methods. 22 In-
deed, the term "nonfunctioning" has been con-
sidered by some a misnomer for this reason. I 
In the patient suspected of harboring a 
nonsecreting tumor, one must be aware that 
larger tumors may cause a mild to moderate 
hyperprolactinemia resulting from the so-
called "stalk-section effect." This disconnec-
tion hyperprolactinemia-stalk compression 
causing loss of dopaminergic inhibition to 
tonic prolactin release-must be distin-
guished from a true prolactinoma. 27 
Under such circumstances, it is rare to see 
prolactin levels in excess of 100 ng/ml, at 
most 150 ng/ml. Consequently, large tumors 
(>2 cm in size) associated with prolactin lev-
els of < 150 ng/ml, and certainly those of 
< 100 ng/ml, should be considered to be 
nonsecretors when planning management 
strategies. In particular one must be cautious 
in expecting such lesions to diminish in size 
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in response co dopaminergic agonists such. as 
bromocriptine. Aside from mild elaboratIon 
of prolaCtin as a result of "stalk-section ef-
feCt " these tumors are characterized by no 
clinical or biochemical abnormality indicat-
ing hormonal excess. 2 1 
To be distinguished from the true non-
functioning tumors are those that secrete the 
alpha-subunit, common to all of the 
glycoprotein hormones. The alpha-subunit 
may be detected immunohistochemically in 
tumor specimens and biochemically in the 
urine; but, as it possesses no biological ac-
tivity, its secretion has no endocrinological 
consequence. 
The exclusive secretion of the alpha-sub-
unit may be difficult ro determine if each of 
the glycoprotein hormones has not been inde-
pendently assayed. For example, thyroid-
stimulating hormone (TSH) secreting rumors 
may secrete excessive quantities of the alpha-
subunit. 34 
Because these tumors are often quite large 
at the time of presentation, varying amounts 
of hypopituitarism may be present. This 
occurs because normal functioning glandular 
tissue is compressed by the tumor, or because 
of interference with blood supply, leading to 
infarction of normal functioning gland. Re-
ports of reversibility of hypopituitarism fol-
lowing surgical decompression indicates the 
possibility for interruption of the hypo-
thalamic-portal pituitary circulation without 
true necrosis of glandular tissue. 2,29 
Surgical Approach 
The trans nasal transsphenoidal approach is 
currently considered the procedure of choice 
for surgical access ro sellar lesions. The first 
successful trans nasal approach to a pituitary 
adenoma was described in 1907 by Schloffer, 
an Austrian rhinologist. 32 His approach was 
adopted and modified by other European 
surgeons, and by Cushing in the United 
States, who introduced the sublabial incision. 
Original high morbidity of the procedure re-
sulted largely from meningitis and the un-
availability of synthetic glucocorticoids to 
supplement patients with lack of pituitary re-
serve during the perioperative period. This 
led to a waning of interest in its use. 
Resurgence of interest in the trans-
sphenoidal approach was popularized by 
Guiot l6 and Hardy, 17 who further refined it 
by the introduction of the operating micro-
scope and fluoroscopic monitoring. Increased 
use of this technique may also be attributed 
to the well-recognized inadequacy of the sub-
frontal approach to achieve removal of the in-
trasellar component of the tumor. Several re-
pores have demonstrated the inherent benefit 
of the transsphenoidal approach in the pri-
mary surgical management of these le-
sions. 10,12.17.18 Favorable results of the 
rranssphenoidal approach also have been re-
ported in the management of visual disturb-
ances from macroadenomas,9,11.41 establish-
ing this as the approach of choice for the 
surgical management of most pituitary tu-
mors, regardless of size. 
From among 1,000 patients with pituitary 
lesions who were operated on via the rrans-
nasal transsphenoidal route, we assessed more 
than 200 who presented with visual loss. Our 
assessment yielded evidence of improved vi-
sion in 81%, unchanged vision in 16%, and 
worsening of vision in 3 %. These results are 
similar to those reported in other large series 
concerning the efficacy of the transsphenoidal 
approach to suprasellar tumors. Visual out-
come after the rranssphenoidal approach is 
equal or superior to the results reported in 
large series of subfrontal explorations for vis-
ual loss. 
Clear documentation exists for the poten-
tial improvement in pituitary function fol-
lowing transsphenoidal adenomectomy with 
careful preservation of normal gland in cases 
with preexisting hypopituitarism. 2.29 The 
efficacy of transsphenoidal surgery in selected 
patients with microadenomas has been estab-
lished, with some reports of greater than 
90% tumor contro1. 30 ,35 In series including 
larger tumors, however, a less optimistic 
50-85% tumor control has been reported 
with surgery alone. 8 ,9,31 
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Transsphenoidal microsurgery for both 
large and small adenomas has acceptable 
mortality and morbidity when done by expe-
rienced surgeons. 5 Of 2,606 microadenomas 
and 2,677 macroadenomas reported in the 
international survey by Zervas,42 the death 
rate was 0.27% and 0.86%, respectively. Di-
rect injury to the hypothalamus seemed to be 
the major cause of surgical death, with 
delayed mortality attributed to fistula and 
meningitis, or as a result of vascular injury. 
Operative morbidity includes persistent or 
permanent diabetes insipidus (D1), the inci-
dence ranging from 1.8% permanent D1 in 
the 505 cases reported by Laws and Kern26 to 
a 17% incidence immediately postoperatively 
with large adenomas as reported by Cohen. 11 
Postoperative CSF fistulas range from 1.0% 
to 4.4% in different series, 13,40 depending 
upon the size of the lesion and follow-up 
time, but they occur disproportionately with 
larger lesions. 5 
Of more than 1,500 cases reviewed at the 
Mayo Clinic by Laws,24 major morbidity 
(stroke, visual loss, vascular injury, men-
ingitis, CSF rhinorrhea, cranial nerve palsy) 
was encountered in 3.5%, and minor mor-
bidity (bleeding, nasal or sinus problems, 
D1, SIADH, transient cranial nerve paresis, 
transient psychosis) occurred in another 3.5% 
of patients. Complications amount to a rela-
tively small percentage of the overall surgical 
experience, emphasizing the relative safety of 
the procedure. 
The rare contraindications to the trans-
sphenoidal approach include: (1) extensive 
lateral tumor growing into the middle fossa 
with minimal midline mass; (2) ectatic car-
otid arteries projecting to the midline; and 
(3) acute sinusitis, which may delay the pro-
cedure for treatment of the infection. Pre-
vious rhinoplasty or submucous resection 
may increase the difficulty of the dissection 
planes, but this should not constitute a con-
traindication to the trans nasal approach. 
Tumor extension into the middle fossa re-
quires careful inspection of imaging evidence 
regarding the precise location of such lateral 
extension. In patients who have not had pre-
vious surgery, our experience has been that 
such lesions gain access to the middle fossa 
by extension through the cavernous sinus. 
Many of these "middle fossa extension" le-
sions remain within the confines of the caver-
nous sinus and extend into the middle fossa 
by ballooning the lateral wall of the caver-
nous sinus. The optimal approach is trans-
sphenoidal, following the extension of the tu-
mor into the cavernous sinus from either the 
sphenoid sinus or, more commonly, the sella 
turcica. 
A detailed description of the transnasal 
transsphenoidal procedure performed at our 
institution has been published elsewhere. 38 
In those aspects of the procedure that specifi-
cally pertain to large pituitary tumors, expo-
sure is critical. This is especially true in in-
trasellar exposure, due to the long operative 
corridor and relatively small sellar target. 
Adequate bony removal is essential to obtain 
complete sellar access. The location of the 
carotid arteries on the coronal MRI should be 
noted, as this information is valuable when 
opening the dura at the lateral margins of the 
sella. 
Characteristicall y, these tumors are soft 
and friable, and at surgery may herniate 
down through the diaphragma sellae after 
evacuation of the intrasellar component; this 
may be facilitated by asking the anesthetist 
to perform a Valsalva maneuver intra-
operatively. Other techniques to promote 
herniation include the infusion of air or saline 
through a previously placed cisternal or lum-
bar catheter. 1,39 
A pure suprasellar tumor, or one that re-
quires suprasellar access may be approached, 
if necessary, by carrying the bony resection 
anterior over the tuberculum sella with expo-
sure of the dura mater lying anterior to the 
circular sinus. A transverse incision may be 
then made in the dura rostral and caudal to 
the circular sinus, with bipolar coagulation 
and transection of the circular sinus, an intra-
dural structure contained between the leaves 
of the dura. Transection of the circular sinus 
will then enable exposure of the suprasellar 
cistern itself, and provide adequate room for 
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suraical resection of tumor in this location. 
Once the mass has been resected, attention 
must be paid to obliteration of the CSF 
fistula if the arachnoid has been violated. As 
early as 1952, Hirsch 19 fully recognized the 
limitations of any intracranial attempt to 
control the leak, as he reported the first suc-
cessful attempt to close a sphenoidal leak fol-
lowing hypophysectomy using a septal 
mucoperichondrial flap. 
During transsphenoidal procedures in 
which the arachnoid has been breached, we 
routinely harvest a fascia lata graft of appro-
priate size to cover the opening. The graft is 
placed on the intradural side of the opening, 
within the intrasellar compartment, and a 
small piece of Marlex mesh is fashioned and 
placed within the sella to maintain the ap-
position of the fascial graft. Placement of the 
fascial graft is critical, as the intracranial 
pressure will tamponade the graft ro the dura 
if properly inserted. 
Prior ro closing, the anesthetist is asked to 
perform a Val salva maneuver to assess the 
functional integrity of the graft. The 
sphenoid sinus behind the graft is then 
packed with fat obtained at the harvest of the 
fascial graft to further buttress the graft in 
position. If no CSF leakage is seen around the 
graft, the retractOr is removed, and the pos-
terior nasai pack is placed against the 
sphenoidal opening. \Ve then perform a lum-
bar puncture with an 18-gauge needle in the 
recovery room and on the first postoperative 
day ro further decrease the chances of a per-
sistent fistula developing. 
In the unusual event that a postoperative 
leak occurs following this protocol, an early 
rerurn is made to the operating room for for-
mal repacking to avoid meningitis. Little is 
to be gained by waiting in these cases as the 
relatively avascular graft is less likely to close 
sponraneously than in the posttraumatic sit-
uation. \VIe routinely obtain nasopharyngeal 
cultures prior to prepping of the nose to 
guide antibiotic coverage should pOSt-
operative meningitis occur. 
The remarkably low morbidity and mor-
tality associated with transsphenoidal resec-
tion of even very large tumors has encouraged 
our group to consider this approach as the 
preferred primary means of resecting almost 
all macroadenomas. Many tumors will herni-
ate into the enlarged sella from the su-
prasellar cistern, subfrontal space, and caver-
nous sinus once the intrasellar component has 
been evacuated. We have, on rare occasions, 
found tumOrS that do not enlarge the sella 
but grow directly into the suprasellar cistern. 
These may present a particular problem; but, 
by mobilizing normal gland and opening 
through the tuberculum sellae as described 
above, one can frequently gain access to the 
suprasellar cistern and extract the tumor. 
Perioperative Managenlent 
Perioperative glucocorticoids should be ad-
ministered to all patients. This is particularly 
important if preoperative endocrine assess-
ment indicates any hypocortisolemia. We 
routinely administer methylprednisolone 40 
mg Q6H or dexamethasone 10 mg Q6H in 
the peri operative period in those cases with 
visual compromise. Medication is usually 
started the day prior to surgery and concinues 
for 1 to 2 &lyS postoperatively; a tapering 
dose is milo red to the individual patient'S 
projected glucocorticoid needs by the prc-
operative endocrine assessment and intra-
operative findings. In those cases without 
visual compromise, lower dosages of these 
high-potency gIucocorticoids ~.vith a more 
rapid postOperative taper may be employed. 
Thyroid function should be assessed pre-
operatively, and the patient treated ro resrore 
the euthyroid state prior to elective surgical 
intervention. The stress of surgery may 
provoke an acute crisis in the patient without 
sufficient reserve; hypothyroidism should be 
a consideration in patients w'ith an Otherwise 
unexplained alteration in postoperarive men-
tal status. 
\\7 e have abandoned the murine use of 
perioperative antibiotics. The liberal use of 
bacitracin-impregnated irrigant has been suf-
ficient, in our experience, to prevent infec-
Strategies for the Management of Nonsecreting Pituitary Adenomas 33 
tion. Nevertheless, the transsphenoidal route 
should be considered only semi-sterile. In the 
advent of postoperative meningitis, therapy 
must begin with antiobiotics to cover colo-
nizing organisms identified from the routine 
preoperative nasopharyngeal culture. 
Serial visual field testing is routinely per-
formed in the recovery room and intensive 
care unit to monitor visual function. In the 
patient with preoperative visual deficit, care-
ful monitoring in the early postoperative pe-
riod is essential. Both the transfrontal and 
transsphenoidal routes are successful in im-
proving vision. 9, 15,40 Immediate post-
operative improvement of vision may 
occur, 14 with a significant improvement usu-
ally within the first 2 weeks, although con-
tinued improvement may occur for up to 12 
months. 20 
More importantly, any loss of vision in the 
postoperative period may indicate an evolv-
ing hemorrhagic complication that may be 
diagnosed by CT scanning. Progressive visual 
deficit with postoperative hematoma in the 
tumor bed would warrant reexploration. 
Early postoperative scanning, both CT and 
MR, may demonstrate false evidence of su-
prasellar hemorrhage due to postoperative 
changes that give the spurious impression of 
a suprasellar hematoma. Consequently, the 
clinical evidence provided by progressive vis-
ual loss remains the primary guide to the 
need for reexploration, supplemented by 
imaging evidence. 
Blood pressure is carefully monitored. Hy-
potensive events must be avoided, especially 
in patients in whom tissue perfusion is al-
ready marginal. We do not, however, rou-
tinely place an intraarterial line in patients 
with an uncomplicated medical history. 
Urine volumes and specific gravities must 
be followed along with sodium levels to 
assess the presence of diabetes insipidus. 
High doses of corticosteroids will frequently 
cause a subclinical state of DI to be manifest; 
we therefore taper corticosteroids as rapidly 
as possible postoperatively. In addition, one 
frequently encounters a secondary stage of 
water retention (?SIADH) following an ini-
tial bout of DI. Once this secondary stage, 
identified by a low serum sodium, is 
finished, the patient may transiently excrete 
a large volume of 10\\1 specific gravity urine. 
This simply represents clearance of excess free 
water and should not be treated, since the 
majority of these patients will come intO 
fluid balance on their own. It is imperative, 
however, to carefully follow the serum so-
dium in order to define this process. 
Prior to discharge, an A.M. fasting serum 
cortisol is obtained to determine the need for 
cortisol replacement. Intraoperative evidence 
of residual normal pituitary gland is also a 
major guide in such considerations. Thyroid 
evaluation is usually done 3 to 4 weeks 
postoperatively, since autonomous function 
of the thyroid may persist for some time. 
Unless clinically indicated, postoperative 
imaging is done no earlier than 6 weeks 
postoperatively, at 3 months in most cases. 
This allows resolution of all operative ar-
tifactual changes and assessment for residual 
tumor. 
Management of the 
Poor-Risk Patient 
In the elderly patient, or any patient with 
a medical illness that may increase the risk of 
complications from general anesthesia or sur-
gery, consideration should be given to pri-
mary radiation therapy (RT) after clinical di-
agnosis of a nonfuctioning pituitary tumor. 
This nonsurgical approach is particularly ap-
propriate in patients who already have hypo-
pituitarism. 
A dose of 4,000 cGy by external beam is 
considered optimal by most radio-
therapists. 3,33 In a series of 12 patients 
treated with RT alone, Chun et al8 described 
a 50% recurrence rate with a 75% local con-
trol following treatment. Other authors re-
port a local control rate of 50-79%, with an 
adequate salvage in cases of recurrence. 23. 36 
In the asymptomatic elderly patient with a 
nonsecreting tumor, intact pituitary func-
tion, and no compromise of the visual sys-
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rem a case can be made for merely monitOr-
ing'rhe patient with routine visual and 
endocrine evaluation, and serial MRI or CT 
scannin'" at least yearly. These tumors may b . 
exhibit a benign course, without reachwg 
symptomatic dimensions within the life ex-
pectancy of the patient. 
Postoperative Radiotherapy 
The rationale for postoperative RT is to 
reduce the incidence of recurrence. Several 
studies suggest improved tumor control w.ith 
the combination of surgery plus radto-
therapy.6,8,9,28 This is especially true in 
large and invasive lesions, which manifest an 
increased rate of recurrence. RT by no means 
insures recurrence-free survival, but the time 
to recurrence may be prolonged. 
Valtonen and Myllymaki37 reported a sur-
prisingly high 36% recurrence rate in pa-
tients with a "total removal" following trans-
frontal craniotomy and postoperative R T, 
with recurrences up to 18 years after therapy. 
Thus, published recurrence rates may be mis-
leading in series with short follow-up times. 
This is an important consideration as mor-
bidity and mortality both increase with re-
operation in cases of recurrence. 25,37 
With functioning pituitary tumors, eval-
uation of postoperative endocrine status may 
give indication as to the effectiveness of sur-
gical removal. However, in nonfunctioning 
lesions the judgment of the surgeon, supple-
mented by postoperative imaging, is the only 
means of assessing the extent of resection and 
the risk of recurrence. 
The surgeon's appreciation of the totality 
of the resection may not be accurate in the 
face of an invasive tumor. The lack of a 
chemical marker in a true nonfunctional tu-
mor makes assessment of cure difficult in the 
postoperative period. Furthermore, in con-
trast to prolactin and growth hormone-secret-
ing tumors, no adjunctive pharmacotherapy 
is available. 
For these reasons, the criteria for selection 
of patients for postoperative R T remain con-
troversial. In general, patients with large tu-
mors that have a high incidence of invasion 
of the dura and are difficult to surgically re-
move should all be considered candidates for 
postOperative RT, especially if the patient is 
hypopituitary postoperatively. Similarly, 
frank cavernous sinus invasion is an indica-
tion for postoperative radiation therapy. In 
those cases where mmor invasion is not evi-
dent, and "tOta}" removal has been achieved, 
routine scanning on a yearly basis may be an 
appropriate strategy, especially if endocrine 
function is intact. 
The Problem of Recurrence 
The patient with a recurrent nonsecreting 
tumor may present a challenge, especially if 
the patient is young and has a normally func-
tioning pi tui tary. I n these cases, further 
treatment must be individualized, with op-
tions including repeat transsphenoidal sur-
gery, salvage R T, or following the patient 
with serial imaging smdies if he/she is func-
tionally intact or stable. Prior radiation ther-
apy may produce thinning of the bone at the 
skull base, and may predispose to 
postoperative leaks, but is never a contrain-
dication to rranssphenoidal surgery. 25 The 
situation is quite different following previous 
frontal craniotomy, which may produce scar-
ring and distorted vascular anatomy, increas-
ing the risk of reoperation. 
Summary 
The diagnosis of a nonsecreting pituitary 
adenoma relies on a constellation of 
radiographic, endocrinological, and clinical 
criteria. The management of the patient 
must be considered primarily surgical, with 
other therapeutic options individualized de-
pending on symptomatology, endocrine sta-
tus, age, and general health. 
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